These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 30132546

  • 1. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
    Tang Y, He H, Sun W, Hu P, Chen X, Xu X.
    Mol Med Rep; 2018 Oct; 18(4):4103-4112. PubMed ID: 30132546
    [Abstract] [Full Text] [Related]

  • 2. Activation of the interleukin-4/signal transducer and activator of transcription 6 signaling pathway and homeodomain-interacting protein kinase 2 production by tonsillar mononuclear cells in IgA nephropathy.
    He L, Peng Y, Liu H, Yin W, Chen X, Peng X, Shao J, Liu Y, Liu F.
    Am J Nephrol; 2013 Oct; 38(4):321-32. PubMed ID: 24107646
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria.
    Nagasawa Y, Yamamoto R, Shinzawa M, Shoji T, Hasuike Y, Nagatoya K, Yamauchi A, Hayashi T, Kuragano T, Moriyama T, Isaka Y.
    Clin Exp Nephrol; 2020 Oct; 24(10):927-934. PubMed ID: 32642919
    [Abstract] [Full Text] [Related]

  • 4. Treatment of IgA nephropathy.
    Pozzi C.
    J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268
    [Abstract] [Full Text] [Related]

  • 5. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
    Zhong Z, Tang Y, Tan J, Tan L, Pei G, Qin W.
    Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
    [Abstract] [Full Text] [Related]

  • 6. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
    Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, K Smerud H, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.
    Pediatr Nephrol; 2017 Jan; 32(1):139-150. PubMed ID: 27557557
    [Abstract] [Full Text] [Related]

  • 7. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.
    Dong J, Peng T, Gao J, Jia X, Yan G, Wang Y.
    BMC Immunol; 2018 Jun 20; 19(1):18. PubMed ID: 29925312
    [Abstract] [Full Text] [Related]

  • 8. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 20; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 9. Corticosteroid in IgA nephropathy with moderate proteinuria: A retrospective cohort study.
    Wang Y, Yu J, Jiang Y, Li J, Yimamuyushan A, Xia X, Fan L, Huang F, Chen W, Liu Q.
    Nephrology (Carlton); 2024 May 20; 29(5):268-277. PubMed ID: 38186010
    [Abstract] [Full Text] [Related]

  • 10. JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.
    Tao J, Mariani L, Eddy S, Maecker H, Kambham N, Mehta K, Hartman J, Wang W, Kretzler M, Lafayette RA.
    Clin J Am Soc Nephrol; 2020 Jul 01; 15(7):973-982. PubMed ID: 32354727
    [Abstract] [Full Text] [Related]

  • 11. Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria.
    Tanaka K, Moriyama T, Iwasaki C, Takei T, Nitta K.
    Clin Exp Nephrol; 2015 Oct 01; 19(5):815-21. PubMed ID: 25475403
    [Abstract] [Full Text] [Related]

  • 12. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
    Riispere Ž, Kuudeberg A, Seppet E, Sepp K, Ilmoja M, Luman M, Kõlvald K, Auerbach A, Ots-Rosenberg M.
    BMC Nephrol; 2017 Mar 14; 18(1):89. PubMed ID: 28292274
    [Abstract] [Full Text] [Related]

  • 13. Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison.
    Ismail G, Obrişcă B, Jurubiţă R, Andronesi A, Sorohan B, Vornicu A, Sinescu I, Hârza M.
    Medicine (Baltimore); 2020 Jun 26; 99(26):e21000. PubMed ID: 32590815
    [Abstract] [Full Text] [Related]

  • 14. Baseline proteinuria, urinary osmotic pressure, and renal function as positive predictors of corticosteroids plus cyclophosphamide treatment efficacy in IgA nephropathy.
    Fang J, Li W, Li D, Tan Z.
    Chin Med J (Engl); 2014 Jun 26; 127(9):1710-4. PubMed ID: 24791879
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
    Kang Z, Li Z, Duan C, Wu T, Xun M, Ding Y, Zhang Y, Zhang L, Yin Y.
    Pediatr Nephrol; 2015 Jul 26; 30(7):1121-9. PubMed ID: 25773534
    [Abstract] [Full Text] [Related]

  • 16. Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study.
    Rivedal M, Haaskjold YL, Eikrem Ø, Bjørneklett R, Marti HP, Knoop T.
    BMC Nephrol; 2024 Jan 29; 25(1):42. PubMed ID: 38287343
    [Abstract] [Full Text] [Related]

  • 17. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
    Shi X, Chen X, Liu S, Zhuang Y, Zhang Y.
    Zhonghua Nei Ke Za Zhi; 2002 Jun 29; 41(6):399-403. PubMed ID: 12137603
    [Abstract] [Full Text] [Related]

  • 18. High serum IgA/C3 ratio better predicts a diagnosis of IgA nephropathy among primary glomerular nephropathy patients with proteinuria ≤ 1 g/d: an observational cross-sectional study.
    Gong WY, Liu M, Luo D, Liu FN, Yin LH, Li YQ, Zhang J, Peng H.
    BMC Nephrol; 2019 Apr 30; 20(1):150. PubMed ID: 31039758
    [Abstract] [Full Text] [Related]

  • 19. Comparison between patients with IgA nephropathy with minimal change disease and patients with minimal change disease.
    Li XW, Cheng SQ, Liang SS, Le WB, Zeng CH, Wang JQ, Liu ZH.
    Clin Nephrol; 2016 May 30; 85(5):273-81. PubMed ID: 26951969
    [Abstract] [Full Text] [Related]

  • 20. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
    Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F.
    J Am Soc Nephrol; 2004 Jan 30; 15(1):157-63. PubMed ID: 14694168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.